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Abstract 
The effects of anaphylatoxin C3a on human neutrophils were studied in comparison with C5a. Both peptides induced a transient shape change 
response and a respiratory burst. In both cases C3a was 50- to 100-times less potent han C5a. A marked chemotactic response with bimodal 
concentration dependence was obtained with C5a, but no neutrophil chemotaxis was observed with C3a. Repeated stimulation led to homologous 
desensitization f shape changes and respiratory burst but no cross-desensitization, indicating that the two anaphylatoxins act through separate 
receptors. The lack of chemotactic activity suggests that C3a is not involved in neutrophil recruitment into infected or inflamed tissues. 
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1. Introduction 
The anaphylatoxins C3a and C5a are generated upon 
complement activation, and are known for their proin- 
flammatory effects [1-3]. C5a is generally recognized as 
a mediator of inflammation with potent attractant and 
activating effects on neutrophil, eosinophil and basophil 
leukocytes [4-7], while the role of C3a is less defined. It 
has been shown that C3a binds to neutrophils [8,9], 
eosinophils and basophils [10]. It induces neutrophil ag- 
gregation [11,12] and morphological changes [13], but 
little or no enzyme release [9,14]. In neutrophils [15] and 
differentiated U937 cells [8,9], C3a increases the cy- 
tosolic free Ca 2+ concentration by a G protein-dependent 
signal transduction pathway different from the one in- 
volved in C5a-mediated neutrophil stimulation. 
We studied the responses of human neutrophils to C3a 
with special attention to functions that are related to 
antimicrobial defence, i.e. the induction of motile behav- 
ior, migration, and the respiratory burst. The data show 
that C3a activates the motor apparatus of the cells (as 
already implied in [13]) and elicits a characteristic, albeit 
weak, respiratory burst, but does not induce chemotaxis 
in vitro. It thus appears that C3a plays only a minor role 
in neutrophil recruitment. 
2. Materials and methods 
2.1. Materials 
Stock solutions of homogenous C3a and C5a prepared from human 
serum [5] were kindly provided by Dr. C.A. Dahinden, Department of
Clinical Immunology, University of Bern, Switzerland; they were fur- 
ther diluted with test buffer (below) containing 0.25% fatty acid-free 
BSA (Boehringer-Mannheim, Rotkreuz, Switzerland). All other chem- 
icals were obtained as described in [16]. 
2.2. Cell preparations 
For the chemotaxis assays, neutrophils were isolated by dextran 
sedimentation f freshly drawn blood from healthy volunteers accord- 
ing to [17]. All other assays were performed using neutrophils prepared 
from donor blood buffy coats [16]. The purified cells were suspended 
in test buffer containing (mM) 130 NaC1, 5.0 NaHCO3, 4.6 KCI, 
5 glucose, 0.05 CaC12, and 20 HEPES, adjusted to pH 7.4 with NaOH, 
and kept above ice at ca. 10*C. 
2.3. Functional assays 
Shape change was assayed by measuring the agonist-induced changes 
in light transmission and 90 ° scattering of stirred neutrophil suspen- 
sions (8 x l0 s cells/rnl) at 37°C [18]. Extinction was calculated from the 
transmission by means of Beer's law. 
Chemotaxis was assessed in multi-well chemotaxis chambers (Neuro 
Probe, Cabin John, MD) by the method escribed in [19]. 
Exocytosis of fl-glucuronidase was determined in neutrophils pre- 
treated with cytochalasin B according to the procedure of Dewald and 
Baggiolini [20]. 
The respiratory burst was followed using a previously described 
real-time chemiluminescence assay for H202 [21]. 
3. Results 
*Corresponding author. Fax: (41) (31) 631 3799. 
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Abbreviations: C3a, serum complement fragment 3a; C5a, serum com- 
plement fragment 5a (anaphylatoxins). 
3.1. Shape change 
Transient changes in extinction and 90 ° light scatter- 
ing were observed after stimulation of suspended neu- 
trophils with either C3a or C5a (Fig. 1). The amplitude 
of the peak response was similar for both anaphylatox- 
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Fig. 1. Shape change responses of human neutrophils. Percent change from resting level in 90 ° light scattering (top) and extinction (bottom) of cells 
stimulated with C3a (A) or C5a (B) at time 0. The tracings are representative of 3 experiments performed with cells from different donors. 
ins, but the progress curves were dramatically different 
and the duration of the C3a response was significantly 
shorter. A plot relating maximum extinction change to 
stimulus concentration shows that C5a was about 50- 
fold more potent han C3a as a stimulus of neutrophil 
shape change (ECs0 = 0.007 and 0.37 nM, respecively; 
Fig. 2). 
3.2. Other functional responses 
The ability of C3a to induce chemotaxis, secretion and 
a respiratory burst was tested. C3a was not chemotactic 
in vitro over a concentration range of 6 orders of magni- 
tude (0.01-1,000 nM) and was virtually inactive as a 
stimulus of exocytosis: only borderline amounts of 
fl-glucuronidase were released from cytochalasin B- 
treated cells up to the highest concentration tested (100 
nM). By contrast, C5a was a powerful inducer of both 
chemotaxis and exocytosis. Significant chemotaxis was 
detected with as little as 50 pM C5a, rising to a maximum 
at 1 nM and declining thereafter (Fig. 3). At 10 nM, C5a 
was four times more potent han C3a in stimulating re- 
lease of fl-glucuronidase from cytochalasin B-treated 
cells. Both anaphylatoxins i duced arapid, transient res- 
piratory burst of roughly the same duration (Fig. 4). 
However, the total yield of H202 was more than 100-fold 
higher upon stimulation with C5a. 
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Fig. 2. Concentration dependence of neutrophil shape change responses 
induced by C3a and C5a. Mean values _+ S.D. of maximal extinction 
changes 10-15 s after stimulation obtained in 3-7 experiments per- 
formed with cells from different donors. 
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Fig. 3. Chemotactic migration of human neutrophils after stimulation 
with C3a or C5a. Mean values + S.D. of the chemotactic index from 
3 experiments performed with cells from different donors. 
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3.3. Receptor desensitization 
Repeated stimulation of neutrophils with C3a led to 
a loss of responsiveness in respiratory burst (Fig. 4) and 
shape change response (Fig. 5). Cells that were fully 
desensitized to C3a, nonetheless, responded normally to 
C5a (Figs. 4 and 5). Prestimulation with C3a did not 
influence the subsequent shape change or respiratory 
burst response to C5a, and prestimulation with C5a did 
not influence responses to C3a (Fig. 5). These data 
strongly suggest that the two anaphylatoxins exert heir 
effects via different receptors. 
4. Discussion 
Neutrophils responded to the anaphylatoxic peptides 
C3a and C5a with a marked shape change that was 
similar in amplitude, but shorter for C3a. C3a also pro- 
voked a respiratory burst (with a yield of H202 that was 
less than 1/100th of that observed with C5a), but was 
virtually inactive as a stimulus of exocytosis, and did not 
induce chemotaxis. Desensitization experiments showed 
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Fig. 4. Respiratory burst of human neutrophils after stimulation with 
C3a or C5a. The responses to40 nM C3a or 10 nM C5a, added to the 
cells as indicated by arrows, are shown. Panel A shows the first 60 s of 
the tracing in panel B (note the difference in vertical scale between 
panels A and B). This result is representative of 3 experiments per- 
formed with cells from different donors. 
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Fig. 5. Cross-desensitization experiments after homologous desensitiza- 
tion with C3a (A) or C5a (B). 90 ° scattering changes of neutrophils 
stimulated repeatedly with C3a (10 nM) or CSa (0.1 nM in A, 30 nM 
in B; arrows). The tracings are representative for 3-4 experiments 
performed with cells from different donors. 
that C3a and C5a did not influence each others re- 
sponses, indicating, in agreement with previous reports 
[9,12], that the two anaphylatoxins act via separate re- 
ceptors. 
The unequal time-course of the shape change tran- 
sients may suggest that C3a and CSa have different ef- 
fects on the cytoskeleton. Alternatively, Yuli and 
Snyderman pointed out that the 'slow' scattering re- 
sponse could reflect secretion [22]. Thus, the short dura- 
tion of C3a-mediated scattering changes may reflect he 
inability of C3a to induce xocytosis. Although the max- 
imal amplitudes of the shape change responses were sim- 
ilar, C3a was about 50-times less potent han CSa. The 
difference inpotency could be partly due to the numbers 
and affinities of the respective receptors (neutrophils 
have 30,000-40,000 C3a [8,9] and 100,000-200,000 C5a 
receptors [23,24] with mean Kd values of 2-30 and 1-2 
nM, respectively). Our data agree with similar potency 
differences described in earlier eports for leukotriene B4 
formation [25] and cell aggregation [11,12] induced by 
these two anaphylatoxins in neutrophils. 
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It is interesting that C3a, despite its pronounced effect 
on shape, was completely inactive as a chemoattractant, 
since shape change is considered a correlate of migration 
[26]. Other events, however, are required for chemotaxis, 
and C3a might be inactive in the expression of adhesion 
receptors which are necessary for neutrophil migration 
on a substrate. 
Together with recently reported ata from other lab- 
oratories, the present results demonstrate that C3a acti- 
vates human neutrophils, although its potency is con- 
siderably lower than that of C5a. The major difference 
between these anaphylatoxins is in chemotaxis and se- 
cretion, which are induced by C5a, but not by C3a. The 
inability to induce chemotaxis suggests that C3a plays a 
lesser ole than other neutrophil-activating agonists and 
chemotactic cytokines in neutrophil-dependent a timi- 
crobial defence. 
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